Prostate Cancer Screening in Men With Germline BRCA2 Mutations
- Conditions
- Prostate Cancer
- Registration Number
- NCT02154672
- Lead Sponsor
- Yale University
- Brief Summary
The purpose of this study is to determine the incidence of prostate cancer in men with the BRCa2 gene mutation as an independent indicator for prostate cancer screening.
- Detailed Description
This is a cohort screening study to prospectively identify the incidence of prostate cancer in a population of BRCA2 carriers. All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing.
Standard of care screening at the Yale Cancer Center for men with a normal prostate cancer risk consists of a PSA test and prostate physical examination beginning at age 50 years and if either is abnormal an MRI of the prostate followed by Fusion-targeted biopsy of the prostate is performed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1
- All men ≥30 years of age with at least a ten-year life expectancy
- A known BRCA2 mutation
- Ability to have an MRI
- Able to give informed consent will be approached to participate in the study
- If a man has received or is currently receiving treatment for prostate cancer
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Prostate Cancer Patients With BRCA2 Mutation Carriers Up to 3 years number of patients with a BRCA2 mutation who are diagnosed with prostate cancer
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Yale University
🇺🇸New Haven, Connecticut, United States